Acomplia could reach sales of $3 billion per year

Share this article:

Sanofi-Aventis' new obesity drug Acomplia could eventually generate sales of over $3 billion a year, its chairman told Reuters news service yesterday.
"I can tell you that for such a product, in my expectations, three (billion dollars) is not too much," Jean-Francois Dehecq said during a meeting of pharmaceutical executives in Brussels, commenting on forecasts for the medicine.
Sanofi-Aventis anticipates the launch of Acomplia, which also helps people quit smoking, to take place in the first part of 2006.
The drug is among the world's most anticipated since a global obesity epidemic threatens the health of millions of people in developed countries.

 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions